J. Nilsson

发表

A systematic literature review of time to return to work and narcotic use after lumbar spinal fusion using minimal invasive and open surgery techniques

S. Vertuani, Xuan Wang, B. Borgman, 2017, BMC Health Services Research.

The role of income in brain tumor patients: a descriptive register-based study

M. Bergqvist, J. Nilsson, G. Holgersson, 2018, Medical Oncology.

Socioeconomy as a prognostic factor for location of death in Swedish palliative cancer patients

M. Bergqvist, J. Nilsson, G. Ullenhag, 2021, BMC Palliative Care.

Burden of herpes zoster and post-herpetic neuralgia in Sweden

J. Nilsson, L. Lindquist, T. Cassel, 2013, BMC Infectious Diseases.

Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy.

J. Bergh, P. Malmström, H. Holte, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.

Jorma Isola, Jonas Bergh, Nils Wilking, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of comorbidity in the management and prognosis in nonsmall cell lung cancer: a population-based study

M. Bergqvist, J. Nilsson, A. Berglund, 2017, Acta oncologica.

High frequency home-based exercise decreases levels of vascular endothelial growth factor in patients with stable angina pectoris

O. Hammarsten, Å. Cider, Maria Bäck, 2015, European journal of preventive cardiology.

Intensive Treatment and Stem Cell Transplantation in Chronic Myelogenous Leukemia: Long-Term Follow-Up

U. Olsson‐Strömberg, G. Gahrton, O. Linder, 2005, Acta Haematologica.

Value of Innovation in Oncology Treatments for Patients in Sweden with Advanced or Metastatic Non-Small Cell Lung Cancer

A. Mcguire, J. Nilsson, A. Stanford, 2016 .

The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a Retrospective Analysis of a Phase II Trial

M. Bergqvist, J. Nilsson, J. Harmenberg, 2017, Asian Pacific journal of cancer prevention : APJCP.

Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.

D. Brattström, M. Bergqvist, S. Ekman, 2015, Anticancer research.

The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy.

R. Henriksson, M. Bergqvist, S. Ekman, 2017, Neoplasma.

Neoadjuvant Cisplatinum Based Combination Chemotherapy Improves Overall Survival in Patients with Invasive Bladder Cancer : A Combined Analysis of Two Nordic Collaborative Studies

L. Holmberg, S. Nilsson, J. Nilsson, 2003 .

Neoadjuvant Cisplatin-Methotrexate Chemotherapy for Invasive Bladder Cancer - Nordic Cystectomy Trial 2

L. Holmberg, S. Nilsson, J. Nilsson, 2002, Scandinavian journal of urology and nephrology.

Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.

J. Bergh, M. Piccart, R. Coombes, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

End‐of‐life care: Where do cancer patients want to die? A systematic review

M. Bergqvist, J. Nilsson, G. Holgersson, 2017, Asia-Pacific journal of clinical oncology.

Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast G

J. Bergh, B. Erikstein, S. Kaasa, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data

K. Ikari, H. Yamanaka, E. Inoue, 2022, PloS one.

Incidence trends in high-grade primary brain tumors in males and females.

R. Henriksson, M. Bergqvist, J. Nilsson, 2017, Oncology letters.

Incidence Rates in Low-Grade Primary Brain Tumors: Are There Differences Between Men and Women? A Systematic Review

R. Henriksson, M. Bergqvist, J. Nilsson, 2016, World journal of oncology.

Basoluminal Carcinoma: A New Biologically and Prognostically Distinct Entity Between Basal and Luminal Breast Cancer

J. Bergh, P. Malmström, B. Erikstein, 2006, Clinical Cancer Research.

Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland.

J. Nilsson, M. Reynolds, P. Lindgren, 2012, Clinical therapeutics.

Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model

M. Jhaveri, J. Nilsson, M. Reynolds, 2013, ClinicoEconomics and outcomes research : CEOR.

The Use of Complementary and Alternative Medicine in Scandinavia.

M. Bergqvist, J. Nilsson, G. Holgersson, 2016, Anticancer research.

PopCover-2.0. Improved Selection of Peptide Sets With Optimal HLA and Pathogen Diversity Coverage

M. Nielsen, A. Sette, J. Nilsson, 2021, Frontiers in Immunology.

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial

J. Bergh, P. Malmström, H. Holte, 2000, The Lancet.

A Cost-Effectiveness Analysis of Minimally Invasive versus Open Surgery Techniques for Lumbar Spinal Fusion in Italy and the United Kingdom.

S. Vertuani, B. Borgman, J. Nilsson, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies.

Sten Nilsson, Per-Uno Malmström, L. Holmberg, 2004, European urology.

Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.

L. Frölich, J. Nilsson, G. Eckerwall, 2011, Journal of Alzheimer's disease : JAD.

No Evidence for Increased Brain Tumour Incidence in the Swedish National Cancer Register Between Years 1980-2012

R. Henriksson, M. Bergqvist, J. Nilsson, 2019, AntiCancer Research.

Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden

M. Weinstein, K. Clements, J. Nilsson, 2016, Acta ophthalmologica.

Use of CAM among cancer patients

M. Bergqvist, J. Nilsson, G. Holgersson, 2023, BMC Complementary Medicine and Therapies.

Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective

M. Aapro, J. Nilsson, J. Eriksson, 2022, Supportive Care in Cancer.

Comorbidities and relevant outcomes, commonly associated with cancer, of patients newly diagnosed with advanced non-small-cell lung cancer in Sweden.

J. Nilsson, N. Justo, S. Linden, 2019, European journal of cancer care.

Retrospective observational cohort study on innovation in oncology and progress in survival: How far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a single population?

A. Mcguire, J. Nilsson, J. Dalén, 2020, PloS one.